Modern Diagnostics
Diagnostic laboratories
CURRENT IMPACT
4500+
Lives impacted so far.
Geographical Focus
- Pan India
Potential Impact
- Reach
8 million
people
Dr Devendra Singh Yadav CMD, Modern Diagnostic & Research Centre Pvt Ltd
The SAMRIDH support was instrumental in our planning for expansion in distant locations. The funding received from SAMRIDH enables us to take advantage of incredible opportunities to setup laboratories in tier 2 and 3 cities of India. Sharing a common vision to strengthen India’s health infrastructure, SAMRIDH is helping us in setting up laboratory infrastructure in tier -2 and 3 cities and integrating them with our existing network of Labs. Thus, it has enabled us to meet our corporate objective of providing ethical and quality diagnostic services to the needy in four states of Jammu & Kashmir, Assam, Madhya Pradesh, and Punjab.
Samridh support
SAMRIDH’s support of INR 2.85 Cr has helped Modern Diagnostics open and operate multiple labs in the target cities. With total funding of INR 20 Cr, including loans and equity, the leverage on SAMRIDH’s support is an impressive 7.01x.
74%
Of existing labs are primarily concentrated in urban areas and hospitals.[1]
1,111
Pathology tests are done in India and 36 imaging tests per one thousand, compared to twenty thousand nine hundred seventy-eight pathology tests in the USA. [2]
Diagnostics play a critical role in the continuum of care with the increasing adoption of evidence-based medicine. It is estimated that nearly 70% of medical decisions are based on laboratory results across the globe[3]. In India, though the menu of 4,500 tests available is comparable to global standards, it is not evenly distributed. In addition, when compared to other countries, diagnostics is significantly underpenetrated in India.
Pathology labs to cater to tier 2 and 3 cities
Their objectives include setting up four pathology labs in tier 2 and 3 cities of Guwahati, Indore, Ajnala, and Jammu, with support from 86 collection centers. The pathology labs will improve access to affordable tests, and reduce turnaround times for routine, specialized, and super-specialized tests. Adoption of digital Histopathology and Cytology will enhance second opinions and super-specialty expertise. Further reduced costs, shorter cycle times, and capacity enhancement for a higher number of samples will make testing more affordable for patients. The operational lab will offer 150 to 200 routine and specialty tests. Finally, steps will be undertaken to obtain accreditation from the National Accreditation Board for Testing and Calibration Laboratories (NABL), reflecting the lab’s adherence to quality standards.
Key Stakeholders
